Ken Griffin Bluebird Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$0.47 - $1.35 $16,355 - $46,980	34,800 Added 15.13%	264,800 $137,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $75,905 - $112,518	-89,300 Reduced 27.97%	230,000 $225,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $226,772 - $436,100	-249,200 Reduced 43.83%	319,300 $408,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $384,516 - $1.41 Million	291,300 Added 105.09%	568,500 $784,000
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $141,336 - $189,540	46,800 Added 20.31%	277,200 $842,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $87,327 - $157,439	31,300 Added 15.72%	230,400 $758,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $256,852 - $672,396	81,800 Added 69.74%	199,100 $633,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $452,944 - $666,465	-78,500 Reduced 40.09%	117,300 $811,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $272,625 - $537,253	-72,700 Reduced 27.08%	195,800 $1.24 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.